Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | ATG7 | O95352 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15183379 | 0.83 | CA1 (0.39) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL13908946 | 0.83 | POLB (0.39) | RNASE1CA1CA2CA12CA9 | |
| SCHEMBL13908942 | 0.82 | KMT2A (0.33) | RNASE1CA1CA2CA12CA9 | |
| SCHEMBL13908921 | 0.78 | SMYD2 (0.33) | RNASE1 | |
| SCHEMBL16367297 | 0.78 | L3MBTL1 (0.40) | CA1CA2CA9ATG7 | |
| SCHEMBL5912259 | 0.74 | CA1 (0.43) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL13908941 | 0.74 | POLB (0.49) | RNASE1CA1CA2CA9ALDH1A1 | |
| SCHEMBL11864009 | 0.70 | CA1 (0.32) | CA1CA2CA12CA9 | |
| SCHEMBL11864020 | 0.70 | CA1 (0.32) | CA1CA2CA12CA9 | |
| SCHEMBL11674209 | 0.70 | CA1 (0.32) | CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090060836-A1 | DERIVATIVES OF 2-NITRO-1,3-IMIDAZOLE COUPLED TO AMINO ACIDS AND DEOXYRIBOSE USEFUL FOR THE DETECTION OF HYPOXIC BIOLOGICAL TISSUE | EBERHARD-KARLS-UNIVERSITAET TUBINGEN UNIVERSITAETSKLINIKUM (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090060836-A1 | DERIVATIVES OF 2-NITRO-1,3-IMIDAZOLE COUPLED TO AMINO ACIDS AND DEOXYRIBOSE USEFUL FOR THE DETECTION OF HYPOXIC BIOLOGICAL TISSUE | EBERHARD-KARLS-UNIVERSITAET TUBINGEN UNIVERSITAETSKLINIKUM (DE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060836-A1 | DERIVATIVES OF 2-NITRO-1,3-IMIDAZOLE COUPLED TO AMINO ACIDS AND DEOXYRIBOSE USEFUL FOR THE DETECTION OF HYPOXIC BIOLOGICAL TISSUE | HIF1AN, HIF1A, HYOU1 | RNASE1 454/4885CA1 513/4885CA2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.